Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $14.56
Previous CloseN/A
Volume45.37K
Average Volume (3M)250.94K
Market Cap
$231.53M
Enterprise Value$58.37
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Aug 06, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume146,274
30 Day Avg. Volume250,943
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.83Price Target Upside380.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$549.50K
Bulls Say, Bears Say
Bulls Say
Strategic Licensing AllianceThe WestGene licensing deal is a structural shift: it pairs Cartesian’s mRNA payloads with an in vivo delivery platform, potentially removing ex vivo manufacturing for some programs. That can lower complexity, accelerate timelines, expand indication breadth and strengthen long‑term competitive positioning across autoimmune CAR‑T opportunities.
Material Non-dilutive Financing / Runway ExtensionA committed credit facility that funds initial and milestone tranches materially extends operational runway, reducing near‑term refinancing pressure. For a clinical‑stage biotech this supports continuity of pivotal trials, BLA preparations and precommercial activities, improving the company's ability to reach value‑inflection milestones without immediate equity dilution.
Governance And Oversight ContinuityStrong shareholder support and reappointment of directors plus ratification of a major auditor signal governance stability and continuity. That reduces execution risk around clinical programs and financial reporting over the coming quarters, supporting consistent strategic oversight during critical development and regulatory milestones.
Bears Say
Heavy Cash BurnSustained large negative operating and free cash flows are a durable constraint: ongoing cash burn forces repeated reliance on external funding, constrains optionality in R&D prioritization, and raises dilution or leverage risk if clinical timelines slip or milestone receipts are delayed despite the recent credit facility.
Negative Equity / Strained Balance SheetSignificant negative equity reflects accumulated losses and limits financial flexibility over months: it elevates recapitalization and dilution risk, can complicate access to favorable financing, and reduces the buffer against adverse trial outcomes or execution delays, making long‑term capital structure stability more fragile.
Deteriorating Revenue And MarginsDeclining revenue and deeply negative margins indicate weak near‑term self‑funding capacity and deteriorating earnings quality. For a clinical‑stage company, loss of revenue diversification and persistent negative profitability increase dependence on financing and make successful execution of late‑stage programs and commercialization more financially challenging.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $14.56 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $231.53M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 10 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 29,381,514 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (380.59% Upside)
$33.83 (380.59% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Stock 12 Month Forecast
Average Price Target
$33.83
▲(380.59% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.17% Insiders
7.32% Mutual Funds
0.10% Other Institutional Investors
43.57% Public Companies and
Individual Investors